Antibiotics needed to treat multidrug-resistant infections in neonates

who-bulletin-thumb.png

This article reviews the World Health Organization (WHO) priority pathogens list relevant to neonatal sepsis and proposes a WHO multiexpert stakeholder meeting to promote the development of a neonatal priority antibiotic development list. The goal is to develop international, interdisciplinary consensus for an accelerated neonatal antibiotic development programme.

GARDP Interactive Activity Report 2021

ar-cover.png

The arrival of COVID-19 has brought profound and often tragic disruptions to every facet of life. In 2021, we have nonetheless witnessed more of the astounding achievements that can be made through global investment into the research and development of diagnostics, vaccines, and treatments.

Financial Report 2021

Financial-report_2019_thumb-Cover.jpg.png

After five years in operation, GARDP has formed numerous partnerships with industry, academia and research institutions in support of its clinical programmes to develop antibiotics for drug-resistant infections for children, newborns with sepsis (a bloodstream infection), sexually transmitted infections and serious bacterial infections. These collaborations span the drug development lifecycle and include screening chemical libraries for antibacterial activity, assessing the viability of potential antibiotic candidates, and the completion of three clinical trials.

GARDP Neonatal Sepsis Study Report 2022

NeoObs-study-results.png

GARDP is working to develop new and improved antibiotics to treat drug-resistant infections in children and babies. This report highlights the findings of a global neonatal sepsis observational study carried out by GARDP and partners at 19 hospitals in 11 countries from 2018 to 2020.

Flomoxef and fosfomycin in combination for the treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance

flomoxef-cover.png

Doi: https://doi.org/10.1093/jac/dkac038 Authors: Christopher A. Darlow,Nicola Farrington,Adam Johnson,Laura McEntee,Jennifer Unsworth,Ana Jimenez-Valverde,Ruwanthi Kolamunnage-Dona,Renata M. A. Da Costa,Sally Ellis,François Franceschi, Mike Sharland,Michael Neely,Laura J. V. Piddock,Shampa Das,William Flomoxef and fosfomycin in combination for the treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance